Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biden Infrastructure Plan Offers Biopharma R&D Carrot, Tax Stick

Inversions Have Come Under Attack In Recent Years

Executive Summary

Tens of billions would go to fund R&D, including Phase I and Phase II development of vaccines. But the plan would also crack down on inversions and offshoring.

You may also be interested in...



From Pricing To Tax Havens: AbbVie On The Hot Seat Again With US Congress

Senate committee seeks details on company’s international tax practices as congress works to implement President Biden’s proposals on corporate tax reform.

Raising Corporate Taxes Would Put US Investment At Risk, J&J CFO Warns

"I don't know why folks are anxious to have a race to the top in terms of rates," Joseph Wolk ways. After US tax reform in 2017, lowering the standard tax rate from 35% to 21%, J&J committed to increasing US investment 15% over the next four years. 

Raising Corporate Taxes Would Put US Investment At Risk, J&J CFO Warns

J&J employs 3,000 more people today than it did before US corporate tax reform in 2017, CFO Wolk said, highlighting the company's US investments.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC144110

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel